Table: Taisho Pharmaceutical HD - 6-MTH group results
Oct 30 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2019 Sep 30, 2018 Mar 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 132.21 129.49 293.50
(+2.1 pct) (-6.6 pct) (+12.2 pct)
Operating 14.68 16.99 33.00
(-13.6 pct) (+11.9 pct) (+5.7 pct)
Recurring 14.98 22.71 37.00
(-34.1 pct) (+27.2 pct) (-9.4 pct)
Net 14.98 42.43 29.50
(-64.7 pct) (+253.1 pct) (-39.3 pct)
EPS 187.68 yen 531.62 yen 369.64 yen
EPS Diluted 187.47 yen 531.14 yen
Ann Div 120.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 70.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10